Radiopharm Theranostics (RADX) Stock: Buy, Sell, or Hold?
RADX - Radiopharm Theranostics Limited American Depositary Shares
$0.90
-0.10 (-9.64%)
▼
5d:
-9.09%
30d:
-40.79%
90d:
-71.43%
WAIT
LOW Confidence
Analysis Updated: Oct 27, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When RADX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RADX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RADX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RADX is currently trading at $0.90, which is considered oversold relative to its 30-day fair value range of $1.00 to $1.51.
Technical Outlook: Technically, RADX is in a strong downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.6% recently.
Market Sentiment: RADX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.14 (+1804.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RADX is in a strong downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.6% recently.
Market Sentiment: RADX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.14 (+1804.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.00 -
$1.51
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.6%)
- BULLISH: Trading 1804.2% below Wall St target ($17.14)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.00 -
$1.51
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.19
Current Trend
Strong Downtrend
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.28
Wall Street Target
$17.14
(+1804.2%)
Revenue Growth (YoY)
-36.9%
Share & Embed Analysis
Last updated: October 28, 2026 12:52 AM ET
Data refreshes hourly during market hours. Next update: 1:52 AM
Data refreshes hourly during market hours. Next update: 1:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RADX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 52 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$368 | 52 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 45 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 71 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 70 BUY |
